Alpha-synuclein interaction with mitochondria is the final mechanism of ferroptotic death induced by erastin in SH-SY5Y cells
This study uses a typical inducer of ferroptosis such as erastin on SH-SY5Y cells, and shows clearly that ferroptotic death of cells is accompanied by the loss of mitochondrial membrane potential and intracellular ATP content along with an accumulation of oxidative stress markers. All these are prevented by ferrostatin-1 and liproxstatin-1. Additionally, cyclosporine A prevents mitochondrial alterations and cell death induced by erastin implying the crucial role of mitochondrial permeability transition pore (mPTP) activation in ferroptotic death. Furthermore, an accumulation of α-synuclein occurs during erastin induced fe...
Source: Cell Research - April 4, 2024 Category: Cytology Authors: Upasana Ganguly Sukhpal Singh Aritri Bir Arindam Ghosh Sankha Shubhra Chakrabarti Reena V Saini Luciano Saso Marco Bisaglia Sasanka Chakrabarti Source Type: research
Alpha-synuclein interaction with mitochondria is the final mechanism of ferroptotic death induced by erastin in SH-SY5Y cells
This study uses a typical inducer of ferroptosis such as erastin on SH-SY5Y cells, and shows clearly that ferroptotic death of cells is accompanied by the loss of mitochondrial membrane potential and intracellular ATP content along with an accumulation of oxidative stress markers. All these are prevented by ferrostatin-1 and liproxstatin-1. Additionally, cyclosporine A prevents mitochondrial alterations and cell death induced by erastin implying the crucial role of mitochondrial permeability transition pore (mPTP) activation in ferroptotic death. Furthermore, an accumulation of α-synuclein occurs during erastin induced fe...
Source: Free Radical Research - April 4, 2024 Category: Research Authors: Upasana Ganguly Sukhpal Singh Aritri Bir Arindam Ghosh Sankha Shubhra Chakrabarti Reena V Saini Luciano Saso Marco Bisaglia Sasanka Chakrabarti Source Type: research
Alpha-synuclein interaction with mitochondria is the final mechanism of ferroptotic death induced by erastin in SH-SY5Y cells
This study uses a typical inducer of ferroptosis such as erastin on SH-SY5Y cells, and shows clearly that ferroptotic death of cells is accompanied by the loss of mitochondrial membrane potential and intracellular ATP content along with an accumulation of oxidative stress markers. All these are prevented by ferrostatin-1 and liproxstatin-1. Additionally, cyclosporine A prevents mitochondrial alterations and cell death induced by erastin implying the crucial role of mitochondrial permeability transition pore (mPTP) activation in ferroptotic death. Furthermore, an accumulation of α-synuclein occurs during erastin induced fe...
Source: Free Radical Research - April 4, 2024 Category: Research Authors: Upasana Ganguly Sukhpal Singh Aritri Bir Arindam Ghosh Sankha Shubhra Chakrabarti Reena V Saini Luciano Saso Marco Bisaglia Sasanka Chakrabarti Source Type: research
Oral Psoriasis Therapies
Oral psoriasis therapies include both older traditional immunosuppressants, such as methotrexate, cyclosporine, and acitretin, as well as newer, more targeted agents, such as apremilast, deucravacitinib, and oral interleukin-23 receptor antagonists. Patients may prefer oral therapies to injectable therapies based on the route of administration. Both older and newer oral psoriasis therapies can be utilized effectively in the treatment of psoriasis. Here, we will review oral agents used in the treatment of psoriasis as well as provide commentary on their role in our current, evolving psoriasis treatment paradigm. (Source: Dermatologic Clinics)
Source: Dermatologic Clinics - April 3, 2024 Category: Dermatology Authors: JaBreia James, Tracey Otto, Julia Gao, Martina L. Porter Source Type: research
Pancytopenia with aplastic anemia in systemic lupus erythematosus: case series and literature review
We report two cases of SLE patients who presented with pancytopenia, with bone marrow biopsy confirmed AA. One case was treated with cyclophosphamide but unfortunately succumbed to Acute Respiratory Distress Syndrome (ARDS), while the other case was managed with rituximab with a good response. Interestingly, both patients were on azathioprine before the diagnosis of AA. A comprehensive search for reported cases of AA in PubMed, Scopus, and the Directory of Open Access Journals databases was performed to enhance the understanding of the diagnostic and management challenges associated with AA in SLE, facilitating ongoing exp...
Source: Rheumatology International - April 2, 2024 Category: Rheumatology Source Type: research
Progressive demyelinating polyneuropathy after hematopoietic cell transplantation in metachromatic leukodystrophy: a case series
AbstractMetachromatic leukodystrophy (MLD) is a neuro-metabolic disorder due to arylsulfatase A deficiency, causing demyelination of the central and peripheral nervous system. Hematopoietic cell transplantation (HCT) can provide a symptomatic and survival benefit for pre-symptomatic and early symptomatic patients by stabilizing CNS disease. This case series, however, illustrates the occurrence of severely progressive polyneuropathy shortly after HCT in two patients with late-infantile, one with late-juvenile, and one with adult MLD, leading to the inability to walk or sit without support. The patients had demyelinating pol...
Source: Journal of Neurology - April 2, 2024 Category: Neurology Source Type: research
Inhaled Cyclosporine-Based Immunosuppression Regimen Can Decrease Systemic Calcineurin Inhibitors Nephrotoxicity in Lung Transplant Patients
Purpose: Although clinical outcomes of lung transplantation (LTx) has improved markedly over the last three decades, a major disadvantage is calcineurin inhibitor (CNI) - related nephrotoxicity. We sought a strategy to maintain lung function using localized immunosuppression with inhaled aerosol cyclosporine (ACsA) while decreasing the nephrotoxic effects of systemic immunosuppression in patients who had developed renal insufficiency after LTx. This strategy would hypothetically locally suppress the lung allograft preventing functional declines related to rejection while avoiding systemic CNI side effects. (Source: The Jou...
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , C. Manthuruthil, N. Ladikos, N. Costa, A. Gandhi, V. Kaza, A. Lawrence, S. Bollineni, L.D. Mahan, M. Mohanka, F. Torres, M. Terrin, A. Iacono Source Type: research
Evaluation of Use of Tacrolimus vs. Cyclosporine on CLAD Incidence and Allograft Survival in the ISHLT Registry
Purpose: The ScanCLAD study reported a lower incidence of CLAD with the use of once daily tacrolimus vs. twice daily cyclosporine. Using the ISHLT Registry data, we evaluated the hypothesis that tacrolimus would be superior to cyclosporine with regards to CLAD development in real world clinical practice. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , K. Walter, H. Hixson, E.A. Belloli, K.M. Chan, A.C. Chang, D.M. Lyu Source Type: research
